ES2647232T3 - Métodos para reducir la ingesta con atracón o la ingesta compulsiva - Google Patents

Métodos para reducir la ingesta con atracón o la ingesta compulsiva Download PDF

Info

Publication number
ES2647232T3
ES2647232T3 ES11844637.6T ES11844637T ES2647232T3 ES 2647232 T3 ES2647232 T3 ES 2647232T3 ES 11844637 T ES11844637 T ES 11844637T ES 2647232 T3 ES2647232 T3 ES 2647232T3
Authority
ES
Spain
Prior art keywords
binge eating
binge
pharmaceutical composition
patient
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11844637.6T
Other languages
English (en)
Spanish (es)
Inventor
Eduardo Dunayevich
Susan Mcelroy
Ron Landbloom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orexigen Therapeutics Inc
Original Assignee
Orexigen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46172302&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2647232(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orexigen Therapeutics Inc filed Critical Orexigen Therapeutics Inc
Application granted granted Critical
Publication of ES2647232T3 publication Critical patent/ES2647232T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
ES11844637.6T 2010-12-03 2011-12-02 Métodos para reducir la ingesta con atracón o la ingesta compulsiva Active ES2647232T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41935410P 2010-12-03 2010-12-03
US419354P 2010-12-03
PCT/US2011/063170 WO2012075453A1 (en) 2010-12-03 2011-12-02 Methods for reducing binge or compulsive eating

Publications (1)

Publication Number Publication Date
ES2647232T3 true ES2647232T3 (es) 2017-12-20

Family

ID=46172302

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11844637.6T Active ES2647232T3 (es) 2010-12-03 2011-12-02 Métodos para reducir la ingesta con atracón o la ingesta compulsiva

Country Status (27)

Country Link
US (2) US20130252995A1 (enExample)
EP (1) EP2646011B1 (enExample)
JP (1) JP2014508717A (enExample)
KR (1) KR20140035319A (enExample)
CN (1) CN103298462A (enExample)
AR (2) AR084093A1 (enExample)
AU (3) AU2011336298B2 (enExample)
BR (1) BR112013015957B1 (enExample)
CA (1) CA2819003A1 (enExample)
CL (1) CL2013001565A1 (enExample)
CY (1) CY1119560T1 (enExample)
DK (1) DK2646011T3 (enExample)
ES (1) ES2647232T3 (enExample)
HR (1) HRP20171678T1 (enExample)
HU (1) HUE034641T2 (enExample)
IL (1) IL226483A0 (enExample)
LT (1) LT2646011T (enExample)
MX (1) MX350304B (enExample)
NO (1) NO2646011T3 (enExample)
PL (1) PL2646011T3 (enExample)
PT (1) PT2646011T (enExample)
RS (1) RS56548B1 (enExample)
RU (1) RU2620913C2 (enExample)
SI (1) SI2646011T1 (enExample)
SM (1) SMT201700537T1 (enExample)
TW (2) TWI536986B (enExample)
WO (1) WO2012075453A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101167579B1 (ko) 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물
PT2135603E (pt) 2005-11-22 2013-04-03 Orexigen Therapeutics Inc Composições e métodos para aumentar a sensibilidade à insulina
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
PL4104824T3 (pl) 2012-06-06 2025-11-12 Nalpropion Pharmaceuticals Llc Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2197250C2 (ru) * 2000-10-30 2003-01-27 Соколовский Сергей Ростиславович Способ лечения наркоманий
KR101167579B1 (ko) 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
DE602007005402D1 (de) 2006-11-09 2010-04-29 Orexigen Therapeutics Inc Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht
GB2447949B (en) * 2007-03-29 2010-03-31 Renasci Consultancy Ltd A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission
US8318813B2 (en) * 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
US20100317572A1 (en) * 2007-12-20 2010-12-16 Neurosearch A/S Pharmaceutical composition comprising tesofensine or its analogue and an anti-obesity compound
KR102385359B1 (ko) * 2010-11-08 2022-04-11 오메로스 코포레이션 Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료

Also Published As

Publication number Publication date
US20130252995A1 (en) 2013-09-26
WO2012075453A1 (en) 2012-06-07
BR112013015957B1 (pt) 2021-07-20
AU2017202793A1 (en) 2017-05-18
NO2646011T3 (enExample) 2018-01-13
AU2011336298A1 (en) 2013-07-11
PT2646011T (pt) 2017-11-17
CN103298462A (zh) 2013-09-11
CA2819003A1 (en) 2012-06-07
RU2620913C2 (ru) 2017-05-30
HUE034641T2 (en) 2018-02-28
PL2646011T3 (pl) 2018-01-31
KR20140035319A (ko) 2014-03-21
BR112013015957A2 (pt) 2019-10-29
LT2646011T (lt) 2017-11-10
JP2014508717A (ja) 2014-04-10
US20210283126A1 (en) 2021-09-16
SMT201700537T1 (it) 2018-01-11
AU2018203921A1 (en) 2018-06-21
EP2646011B1 (en) 2017-08-16
RS56548B1 (sr) 2018-02-28
HRP20171678T1 (hr) 2017-12-15
IL226483A0 (en) 2013-07-31
TWI536986B (zh) 2016-06-11
DK2646011T3 (da) 2017-11-20
AU2017202793B2 (en) 2018-03-08
TW201228659A (en) 2012-07-16
CL2013001565A1 (es) 2014-04-04
EP2646011A1 (en) 2013-10-09
MX2013006070A (es) 2013-07-29
RU2013127420A (ru) 2015-01-10
CY1119560T1 (el) 2018-03-07
MX350304B (es) 2017-09-04
SI2646011T1 (en) 2018-01-31
TW201735912A (zh) 2017-10-16
AR124497A2 (es) 2023-04-05
AU2011336298B2 (en) 2017-03-02
AR084093A1 (es) 2013-04-17
EP2646011A4 (en) 2014-04-23

Similar Documents

Publication Publication Date Title
AU2017202793B2 (en) Methods for Reducing Binge or Compulsive Eating
Taliou et al. An open-label pilot study of a formulation containing the anti-inflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders
Cardinali et al. New developments in the treatment of primary insomnia in elderly patients: focus on prolonged-release melatonin [Corrigendum]
Al-Omiri et al. Psychological profiles in patients with recurrent aphthous ulcers
TWI656871B (zh) 用於治療創傷後壓力症候群之方法
AU2018203271A1 (en) Methods of Treating Overweight and Obesity
ES2784240T3 (es) Composiciones farmacéuticas que comprenden DGLA y uso de las mismas
Singh et al. Introduction to Adolescent Health and LifestyleRelated Diseases
Preston et al. Medical and Psychosocial Considerations in Older Adults
Fujioka Sustained-release naltrexone/bupropion-a novel pharmacologic approach to obesity and food craving
Tuite et al. Parkinson's disease: A guide to patient care
HK1188148B (en) Methods for reducing binge or compulsive eating
HK1188148A (en) Methods for reducing binge or compulsive eating
US20250375414A1 (en) Urolithin combinations
Watkins et al. Physical Health in the Context of Mental Health
Jamil et al. WA 98104, USA e-mail: annisa_j@ hotmail. com
Roller et al. Disease state management: Parkinson's disease
Strini Association between oral health, quality of life, salivary cortisol levels and alpha-amylase activity in institutionalized elderly
Urtane et al. Compliance-related problems of medicines in the pharmaceutical practise
Bavuma The Effect of a Homeopathic Complex (Amylenum nitrosum 6ch, Crataegus oxyacantha 6ch, Natrum muriaticum 6ch and Scutellaria lateriflora 6ch) on Blood Pressure in Adults with Refractory Hypertension
Weingärtner et al. Effects of a diet supplementation with plant sterols on circulating monocytes in humans: A prospective, double-blind, randomized, placebo-controlled, cross-over study
TUCKER Chamomile Reduces Mild Generalized Anxiety
Alexandrov et al. The Scientific Session Devoted To The 70th Anniversary Of The Medical College Of Varna October 5, 2012 Varna
Reid INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH
Barnes Understanding the violent resident.